HER2 expression in salivary duct carcinoma

DOI 36 References
  • Suzuki Takayoshi
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Kano Satoshi
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Oridate Nobuhiko
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Honma Akihiro
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Suzuki Seigo
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Hatakeyama Hiromitsu
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Mizumachi Takatsugu
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Furusawa Jun
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Sakashita Tomohiro
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine
  • Fukuda Satoshi
    Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine

Bibliographic Information

Other Title
  • 唾液導管癌におけるHER2の発現解析

Search this article

Abstract

Salivary duct carcinoma histologically resembles an invasive mammary ductal carcinoma and is a malignant tumor with a poor prognosis. The rarity of this carcinoma has resulted in a lack of consensus on its chemotherapy regimen. In recent years, HER2 overexpression has been reported in not only breast cancer but also salivary duct carcinoma, so we performed an immunostaining on the surgical specimens of salivary duct carcinoma and analyzed the relationship between HER2 expression and the clinical background. As a result, 3 cases were found to be HER2-positive. In salivary gland carcinomas, the HER2 positive rate was 60% in salivary duct carcinomas, 0% in adenoid cystic carcinomas, 17% in mucoepidermoid carcinomas, 38% in adenocarcinomas. For the examination of pathological grade in salivary duct carcinoma, all HER2-positive patients belonged in a pathological high-grade group, whereas all HER2-negative cases belonged in a low-grade group. This result suggests a relation between HER2 expression and pathological grade. It is hoped that a new treatment strategy using the anti-HER2 antibody will be developed for HER2-positive salivary duct carcinoma.

Journal

References(36)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top